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Abstract
Background: Lymphocytic hypophysitis is an organ-speciﬁc autoimmune disease of the pituitary gland.
A speciﬁc and sensitive serological test currently does not exist to aid in the diagnosis.
Objective: To identify target autoantigens in lymphocytic hypophysitis and develop a diagnostic assay
for these proteins.
Design/methods: A pituitary cDNA expression library was immunoscreened using sera from four
patients with lymphocytic hypophysitis. Relevant cDNA clones from screening, along with previously
identiﬁed autoantigens pituitary gland-speciﬁc factor 1a and 2 (PGSF1a and PGSF2) and neuron-
speciﬁc enolase (NSE) were tested in an in vitro transcription and translation immunoprecipitation
assay. The corticotroph-speciﬁc transcription factor, TPIT, was investigated separately as a candidate
autoantigen.
Results: Signiﬁcantly positive autoantibody reactivity against TPIT was found in 9/86 hypophysitis
patients vs 1/90 controls (PZ0.018). The reactivity against TPIT was not speciﬁc for lymphocytic
hypophysitis with autoantibodies detectable in the sera from patients with other autoimmune
endocrine diseases. Autoantibodies were also detected against chromodomain-helicase-DNA binding
protein 8, presynaptic cytomatrix protein (piccolo), Ca
2C-dependent secretion activator, PGSF2 and
NSE in serum samples from patients with lymphocytic hypophysitis, but at a frequency that did
not differ from healthy controls. Importantly, 8/86 patients with lymphocytic hypophysitis had
autoantibodies against any two autoantigens in comparison with 0/90 controls (PZ0.0093).
Conclusions: TPIT, a corticotroph-speciﬁc transcription factor, was identiﬁed as a target autoantigen in
10.5% of patients with lymphocytic hypophysitis. Further autoantigens related to vesicle processing
were also identiﬁed as potential autoantigens with different immunoreactivity patterns in patients
and controls.
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Introduction
Lymphocytic hypophysitis is part of the spectrum of
organ-speciﬁc autoimmune endocrine diseases and is
characterised by the inﬁltration of self-reactive
T-lymphocytes into the pituitary gland. The disease is
more frequently seen in females than males at a ratio of
6:1 and has a striking association with pregnancy (1).
In the acute phase, patients usually present with
headaches and visual disturbances due to an upwardly
expanding pituitary mass that mimics an adenoma (2).
Corticotrophs are often the ﬁrst cell type to be affected,
in contrast to pituitary adenoma where they are usually
the last to fail (3, 4, 5). The ensuing secondary adrenal
insufﬁciency is potentially fatal. In chronic cases,
the ongoing autoimmune process can cause post-
inﬂammatory ﬁbrosis leading to pituitary gland atrophy
and an empty sella syndrome (6, 7, 8).
The pituitary mass in lymphocytic hypophysitis can
be indistinguishable from that of a pituitary adenoma
on MRI. Pituitary biopsy has been used to both alleviate
the symptoms of the pituitary mass and to diagnose the
disease on histological grounds. Pituitary biopsy can,
however, lead to permanent pituitary failure and
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to reduce the size of the mass has been recommended
in suspected cases.
High-titre autoantibodies are a characteristic feature
of many autoimmune diseases. They can often be
detected years before the onset of the disease and can
be good predictors of disease progression and outcome
(9, 10). Pituitary autoantibodies have been studied in
various autoimmune diseases by a number of tech-
niques including immunoﬂuorescence (IF) (11, 12, 13,
14, 15), immunoblotting (16) and more recently
immune screeningof cDNA expression libraries followed
by radioligand immunoprecipitation assay (17) to
identify the autoantigens targeted. Indirect IF has the
potential to detect autoantibodies to as yet unchar-
acterised autoantigens, although the method is
probably not sensitive enough in many cases (1).
Immunoblotting recognises linear epitopes and identi-
ﬁes autoantigens by molecular weight (16) but not
cellular localisation (as in IF), whereas immunoprecipi-
tation requires a tertiary structure.
A number of potential autoantigens have been
proposed in lymphocytic hypophysitis including
a-enolase (18, 19, 20), neuron-speciﬁc enolase (NSE)
(20),G H(21, 22), pituitary gland-speciﬁc factors 1a
and 2 (PGSF1a and PGSF2) (17), secretogranin II (23)
and most recently chromosome 14 open reading frame
166 and chorionic somatomammotropin (24).
Although some are undoubtedly markers of an
underlying autoimmune process, they are not always
speciﬁc to pituitary disease. The major target autoanti-
gens in lymphocytic hypophysitis remain unknown.
This study aimed to identify potential target auto-
antigens in lymphocytic hypophysitis by screening a
pituitary cDNA expression library. The cDNA clones
identiﬁed by sera from patients with lymphocytic
hypophysitis were subsequently evaluated using
in vitro transcription and translation (ITT) followed by
immunoprecipitation with patient and healthy control
serum. We also tested the previously identiﬁed pituitary
autoantigens NSE, PGFS1a, PGFS2 and a potential
novel candidate, TPIT, a pituitary-speciﬁc transcription
factor essential for development of the corticotroph
lineage (25, 26).
Methods
Patients
Serum samples were collected for analysis from 86
patients with lymphocytic hypophysitis, including 21
biopsy-proven patients and 65 suspected cases of
lymphocytic hypophysitis. The suspected cases were
further sub-classiﬁed into groups consisting of 43
patients with ‘suspected lymphocytic hypophysitis’,
ten patients with isolated ACTH deﬁciency, six patients
with lymphocytic hypophysitis that had progressed to
empty sella, two patients with isolated ACTH deﬁciency
and an empty sella and four patients with diabetes
insipidus (neuro-infundibulo-hypophysitis). In the spec-
trum of suspected cases, the diagnosis was considered
likely by the referring endocrinologist, usually on the
basis of clinical history, examination and MRI scan
appearance. Serum samples were also obtained from
144 patients with other autoimmune endocrine
diseases comprising 14 patients with Addison’s disease,
20 with autoimmune polyendocrine syndrome type 1
(APS1), 20 with Graves’ disease, 20 with Hashimoto’s
thyroiditis, and 20 with type 1 diabetes mellitus.
A separate group of 50 patients with isolated ACTH
deﬁciency was also used for comparison. This latter
group has been investigated extensively (27). Serum
samples collected from 90 healthy Australian blood
donors served as controls in all experiments.
Ethical approval was obtained from the Committee
of Ethics, Faculty of Medicine, Uppsala University, the
Human Research Ethics Committees of the Hunter
Area Health Service and University of Newcastle
(9706183.13) and the Australian Red Cross Blood
Bank Ethics Committee, with informed, written consent
from all patients and controls.
Immunoscreening of a human pituitary cDNA
library
Serum samples from four patients with lymphocytic
hypophysitis (one biopsy proven and three suspected
cases) were chosen for immunoscreening of a pituitary
cDNA expression library on the basis of high-titre
pituitaryautoantibodies detected byan immunoblotting
assay of pituitary cytosolic proteins (4) and a classical
clinical history. The pituitary cDNA expression library
(28) was immunoscreened separately with all four
patient sera (diluted 1:200) as described previously
(29). In vitro excision of the pBK-CMV phagemid
vectors from the ZAP express library vector was
performed according to the manufacturer’s instructions
(Stratagene, La Jolla, CA, USA). The isolated cDNA
clones were partially sequenced using a dye-terminator
sequencing kit (Amersham Pharmacia Biotech) and
ABI 3730 sequencer (Perkin Elmer Applied Biosystems,
Foster City, CA, USA). cDNA clones were identiﬁed by
comparison of the sequencing data against available
databases using BLAST.
Potential candidate autoantigens
The corticotroph-speciﬁc transcription factor, TPIT (also
referred to as T-box 19) has been identiﬁed as the
causative gene in isolated ACTH deﬁciency of neonatal
onset. Hence, it was chosen for study as corticotroph
cells tend to be preferentially targeted in lymphocytic
hypophysitis resulting in isolated ACTH deﬁciency.
A full-length cDNA TPIT clone was kindly donated by
Dr Jacques Drouin (Montreal, Canada).
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Full-length cDNA clones PGSF1a and PGSF2 were
kindly donated by Dr Ke-ita Tatsumi (Japan) and NSE
was purchased from the clone database (Image Clone
3629603).
ITT of autoantigens and immunoprecipitation
All library cDNA clones identiﬁed by immunoscreening
that were of interest, as well as TPIT, PGSF1a, PGSF2
a n dN S E ,w e r es u b c l o n e di n t ot h ep T N Tv e c t o r
(Promega) by double-restriction-enzyme digestion for
improved efﬁciency of ITT. Inserts were re-veriﬁed by
sequencing as above. A full-length clone encoding rat
Ca
2C-dependent secretion activator (rCADPS) protein
was kindly provided by Dr Tom Martin (Michigan),
which was also subcloned into the pTNT vector.
Autoantigens were expressed using an ITT assay to
determine the frequency and speciﬁcity of immuno-
reactivity against these proteins. Recombinant
35S-radiolabelled proteins were produced by ITT in an
Sp6 Quick coupled reticulocyte lysate system (Promega)
and used for immunoprecipitation with patient sera as
described previously (30). The patient serum from
which the respective cDNA clone was isolated by
immunoscreening the pituitary cDNA library was used
as the positive control and 4% BSA (Sigma) was used as
the negative control. Positive and negative controls were
run in triplicate, whereas all other serawere analysed in
duplicate. Results were expressed as an antibody index
(c.p.m. sample/mean c.p.m. of healthy controls). The
upper normal autoantibody index was set at the mean
of the unequivocally negative healthy blood donors plus
3 S.D. for all autoantigens tested.
Statistical analysis
A c
2-test was performed to determine the probability of
analysed autoantigens as signiﬁcant target autoanti-
gens in lymphocytic hypophysitis. Yates’ correction was
applied due to consistently small group sizes. A P value
of !0.05 was considered signiﬁcant.
Results
Isolation and identiﬁcation of potential
autoantigens from immunoscreening of a
pituitary cDNA library
A pituitary cDNA expression library was immuno-
screened with sera from four patients with lympho-
cytic hypophysitis: one biopsy proven and three
suspected cases, previously shown to have high-titre
pituitary autoantibodies on immunoblotting (4).A
t o t a lo f5 8i n d i v i d u a lc D N Ac l o n e sw e r ei s o l a t e d
and partially sequenced. A single cDNA clone encoding
chromodomain-helicase-DNA binding protein 8
(CHD8) was independently identiﬁed on separate
screenings by two different patients’ sera. On compari-
son with the GenBank database (GenBank accession
NM_020920.2), the partial cDNA sequence isolated
from the library from both patients was found to encode
the carboxyl-terminal region of the 2302 amino acid,
260 kDa CHD8 protein. The recombinant protein
produced by ITT was efﬁciently immunoprecipitated
by the two screening sera and hence was selected for
additional analyses.
From the remaining cDNA clones, a subset with
interesting functional characteristics was chosen for
testing with ITT. When transcribed and translated into
the immunoprecipitation assay system, most of the
recombinant proteins were recognised solely by the
screening serum or no sera at all. Two proteins
encoding Piccolo (presynaptic cytomatrix protein) and
CADPS were each immunoprecipitated by the screening
serum as well as additional lymphocytic hypophysitis
patients, but not by any of the healthy controls and
therefore were selected for further investigation.
Two cDNA clones isolated from the biopsy-proven
patient sera used for immunoscreening encoded a small
portion of the 50 end of the piccolo gene, the full length
of which is reported to encode a 5142 amino acid
protein, with a 4935 amino acids transcript variant also
being identiﬁed (GenBank accessions NM_033026.4
and NM_014510.2 respectively).
Three transcript variants for the human CADPS gene
located on chromosome 3p14.2 have been reported
to differ in the 30 nucleotide sequence of the gene.
When compared with the GenBank mRNA reference
sequences (variant 1: accession ID NM_003716,
variant 2: accession ID NM_183394 and variant 3:
accession ID NM_183393) the partial cDNA clone
encoding CADPS extracted from the pituitary library
matches the entire sequence of all three variants
from nucleotide position 951 (the end of exon 4). The
N-terminal protein sequence is crucial for correct
protein folding of the CADPS protein, therefore
a full-length rCADPS was obtained and used for all
further analyses. The rat homologue is located
on chromosome 15p16 and shares 98% homology
with human CADPS protein.
Autoantibody analysis of library
autoantigens CHD8, piccolo and rCADPS
To ascertain the speciﬁcity of CHD8, piccolo and
rCADPS (full length) as autoantigens,
35S-methionine-
labelled proteins were immunoprecipitated against
sera from 86 patients with lymphocytic hypophysitis
and 90 healthy blood donors (Table 1).
CHD8 autoantibodies were detected in the sera from
seven of the 86 (8.14%) patients with lymphocytic
hypophysitis including two of the 21 (9.52%) patients
with biopsy-proven disease, four of the 43 (9.30%)
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with suspected hypophysitis with diabetes insipidus as
the single presenting symptom. Positive immunoreac-
tivity was also observed in three of the 90 (3.33%)
healthy controls (Supplementary Figure 1, see section
on supplementary data given at the end of this article,
panel A). The frequency of autoantibodies in lympho-
cytic hypophysitis patients was not signiﬁcantly
different from healthy controls, PZ0.2932 (c
2-test
with Yates’ correction).
Piccolo autoantibodies were found in three of the 86
(3.49%) patients with lymphocytic hypophysitis com-
prising one of the 21 (4.76%) biopsy-proven patients,
one of the 43 (2.33%) patients with suspected
lymphocytic hypophysitis and a single patient of ten
(10.0%) with isolated ACTH deﬁciency. Autoantibodies
were also detected in two of the 90 (2.22%) healthy
c o n t r o l s ,o fw h i c ho n eh a de x t r e m e l yh i g h - t i t r e
autoantibodies in comparison with the control
screening serum (Supplementary Figure 1, panel B).
Low-titre autoantibodies against the recombinant
rCADPS protein were identiﬁed in the sera of 12
of the 86 (14%) lymphocytic hypophysitis patients.
Of these 12, three were biopsy proven cases (three of
21, 14.3%), six were suspected hypophysitis (six of 43,
14%), and single cases with isolated ACTH deﬁciency
(one of ten, 10%), empty sella as a late stage of
hypophysitis (one of six, 16.7%) and isolated ACTH
deﬁciency with empty sella (one of two, 50%). None of
the four patients with diabetes insipidus had these
autoantibodies. However, a similar frequency of CADPS
autoantibodies was also observed in healthy controls
with 11 of the 90 (12.2%) considered positive
(Supplementary Figure 1, panel C).
Potential candidate autoantigen TPIT
A positive autoantibody index was seen against TPIT
in nine of the 86 (10.5%) patients with lymphocytic
hypophysitis. These included one of the 21 (4.76%)
biopsy-proven patients, four of the 43 (9.30%) patients
with suspected lymphocytic hypophysitis, one of the
ten (10.0%) patients with ACTH deﬁciency, one of
the six (16.7%) patients with empty sella and two
of the four (50%) patients with diabetes insipidus.
Immunoreactivity was only detected in one of the 90
(1.11%) healthycontrols (Fig. 1). Patients with lympho-
cytichypophysitishadasigniﬁcantlyhigherfrequencyof
autoantibodies against TPIT than that of healthy
controls, PZ0.0186 (c
2-test with Yates’ correction).
To determine whether TPIT autoantibodies were
speciﬁc for lymphocytic hypophysitis, the autoantibody
status of patients with other autoimmune endocrine
diseases was investigated. Autoantibodies against TPIT
were detected in the serum from two patients with
Addison’s disease, one patient with APS1, one patient
with Graves’ disease, two patients with Hashimoto’s
thyroiditis, one type 1 diabetes patient (six of the 94
patients vs nine of the 86 patients with hypophysitis,
PZ0.47 (c
2-test with Yates’ correction) (Fig. 1).
Two of the ﬁfty patients with isolated ACTH
deﬁciency had TPIT autoantibodies (Fig. 1).
Previously reported candidate autoantigens
The frequency and speciﬁcity of autoantibodies in
lymphocytic hypophysitis sera were also determined
with the previously described pituitary autoantigens
PGSF1a, PGSF2 and NSE against the panel of 86
patients with lymphocytic hypophysitis and 90 healthy
blood donors (Table 1).
Insufﬁcient
35S-methionine incorporation was
obtained with PGSF1a despite subcloning into the
pTNT vector. Therefore, no immunoprecipitation
experiments were conducted with this autoantigen.
PGSF2 autoantibodies were detected in the sera of
two of the 21 (9.52%) biopsy-proven patients, one of
the 43 (2.33%) suspected cases, one of the six (16.7%)
patients with empty sella and one of the four (25%)
patients with diabetes insipidus compared with two of
Table 1 Immunoreactivity speciﬁcity against lymphocytic hypo-
physitis candidate autoantigens.
Autoantibody (positive/total (%))
Autoantigen
Lymphocytic
hypophysitis Healthy controls P*
TPIT 9/86 (10.47) 1/90 (1.11) 0.0186
†
CHD8 7/86 (8.14) 3/90 (2.22) 0.2932
Piccolo 3/86 (3.49) 2/90 (2.22) 0.9563
CADPS 12/86 (13.95) 11/90 (12.22) 0.9058
PGSF2 5/86 (5.81) 2/90 (2.22) 0.4048
NSE 2/86 (2.33) 0/90 (0.00) 0.4571
Any 2 AutoAg 8/86 (9.30) 0/90 (0.00) 0.0093
†
*Calculated by c
2-test with Yates’ correction,
†P!0.05.
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Figure 1 Analysis of autoantibodies against TPIT in sera from
patients with lymphocytic hypophysitis (LyH; nZ86), healthy
controls (Ctrls; nZ80), Addison’s disease (AD; nZ14), APS1
(nZ20), Graves’ disease (GD; nZ20), Hashimoto’s thyroiditis (HT;
nZ20), type 1 diabetes mellitus (IDDM; nZ20) and isolated ACTH
deﬁciency (ACTH; nZ50). The broken line indicates the upper limit
of the normal range calculated by the average autoantibody index
of the negative healthy controls plus 3 S.D. (limit Z1.62).
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Figure 1, panel D). The difference was not statistically
signiﬁcant.
Autoantibodies were found against the NSE recombi-
nant protein in two of the 86 (2.33%) patients with
lymphocytic hypophysitis, one patient (one of the six,
16.7%) with empty sella and a single patient (one of the
two, 50%) with empty sella syndrome combined with
isolated ACTH deﬁciency. No autoantibodies against
NSE were detected in the sera from healthy controls
(Supplementary Figure 1, panel E).
Patients with multiple autoantibody
reactivity
In addition, eight of the 86 patients with lympho-
cytic hypophysitis had positive autoantibodies against
two autoantigens in comparison to none of the 90
controls,PZ0.0093(c
2-testwithYates’correction).Two
patients (one biopsy proven and one ‘suspected’) had
positive immunoreactivity to both CHD8 and PGSF2.
Two further patients (one biopsy-proven case and one
patient with diabetes insipidus) had a positive autoanti-
body index for CHD8 and TPIT. A single biopsy-proven
patient had both piccolo and CADPS autoantibodies,
while a ‘suspected’ lymphocytic hypophysitis patient
showed immunoreactivity against CHD8 and CADPS.
A patient diagnosed with empty sella syndrome had
autoantibodies against TPIT and NSE and a further
patient with empty sella syndrome and isolated ACTH
deﬁciency was positive for CADPS and NSE autoanti-
bodies. None of the healthy controls with immunoreac-
tivity were positive for more than a single autoantigen.
Discussion
This study identiﬁed TPITas a minor target autoantigen
in lymphocytic hypophysitis when tested in an
immunoprecipitation assay. A number of other potential
autoantigens were found, including CHD8 (a DNA-
binding protein), Piccolo (a presynaptic cytomatrix
protein associated with the active zone) and a CADPS.
These proteins are involved in vesicle processing that is
fundamental to pituitary peptide hormone release.
The transcription factor TPIT was chosen as a
candidate pituitary autoantigen as it is essential for
the terminal differentiation of pituitary pro-opiomela-
nocortin-expressing cells and is cell speciﬁc (25, 26).
Corticotrophs are often the ﬁrst cell type to be affected in
lymphocytic hypophysitis and some cases of isolated
ACTH deﬁciency are probably autoimmune (4, 27).
Mutations in the TPIT gene cause neonatal isolated
ACTH deﬁciency (25, 26, 31). TPIT was identiﬁed as a
signiﬁcant autoantigen in 10.5% of patients with
hypophysitis. So far, from our data, we could not link
TPIT reactivity to speciﬁc clinical subtypes of hypo-
physitis. Interestingly, autoantibodies were not only
conﬁned to those patients with isolated ACTH deﬁciency
but were also detected in two patients with diabetes
insipidus as the presenting symptom of presumed
infundibuloneurohypophysitis. In one patient, MRI
scan showed stalk thickening and enlargement of the
anterior pituitary with uniform enhancement. Diabetes
insipidus has been associated with vasopressin cell
antibodies in the hypothalamus using IF (14, 32). TPIT
autoantibodies were also detected in patients with other
autoimmune endocrine diseases and hence may not be
speciﬁc for lymphocytic hypophysitis. It cannot be
assumed that TPIT autoantibodies are non-speciﬁc in
this setting as coexistent hypophysitis has been
described at autopsy in patients with Addison’s disease
and up to 10% of patients with Hashimoto’s thyroiditis
have been shown to have pituitary antibodies by ELISA
(33) and IF (34). Although a transcription factor as an
autoantigen appears counterintuitive and the
mechanism of autoantibody formation is not known,
there is a precedent in SOX9 and SOX10 found invitiligo
(35). Recently, autoantibodies to the pituitary transcrip-
tion factor PiT-1, detected by immunoblotting and
antibody-speciﬁc ELISA, have been described in patients
with late onset hypopituitarism and polyglandular
autoimmunity (36). Interestingly, mutations in both
TPIT and PiT-1 give rise to hypopituitarism, i.e.
monogenic disorders that can be mimicked by acquired
autoimmune hypophysitis.
CHD8 was isolated independently by the sera from
two patients with suspected lymphocytic hypophysitis
on immunoscreening of the pituitary library. Given the
rarity of this disorder, this would be an amazing
coincidence; therefore, the protein was considered a
strong candidate as a pituitaryautoantigen. The protein
is a chromatin remodelling ATPase of the SNF2 family,
that regulates gene expression. Its speciﬁc role is to bind
p53 and suppress its function, therebyacting as an anti-
apoptotic factor (37). Autoantibodies were detected
in an additional ﬁve patients with lymphocytic hypo-
physitis (two biopsy proven); however they were not
signiﬁcantly more frequent than in healthy controls.
The secretion of hormones, neurotransmitters and
peptides from neurons, neuroendocrine and endocrine
cells is regulated by the Ca
2C-dependent fusion of
secretory vesicles with the plasma membrane (38, 39).
Two types of secretory vesicles, small clear synaptic
vesicles and large dense-core vesicles, are essential to
the secretion process of packaging, docking, priming
and fusion. This is a fundamental route for the secretion
of pituitary peptide hormones in the pituitary, the
disruption of which could lead to hormonal insufﬁcien-
cies. Secretogranin II, which is involved in this process,
has previously been isolated from screening of the same
pituitary library used in this study (23). The protein is
abundantlyexpressed in gonadotrophs, thyrotrophs and
corticotrophs (40) a n di sb e l i e v e dt om e d i a t et h e
packaging or sorting of peptide hormones and neuro-
peptides into granules of neuroendocrine cells and the
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isolated and identiﬁed two further candidate auto-
antigens, CADPS and piccolo, both related to vesicle
processing.
Piccolo is a presynaptic cytomatrix protein associated
with the active zone of neurons and neuroendocrine
cells (42), which is a specialised region where synaptic
vesicles dock and fuse to release neurotransmitter.
piccolo and bassoon (a homologous protein) function
as tethering proteins that mediate efﬁcient synaptic
vesicle clustering but do not directly participate in
neurotransmitter release (43). In particular, piccolo
functions as a Ca
2C sensor in exocytosis of this process
(44). Autoantibodies against piccolo were detected in
8% of patients with lymphocytic hypophysitis; however,
this was not statistically different from controls. The
reason for the extremely high titre in one healthy
control is unexplained.
CADPS plays a fundamental role in the Ca
2C-
regulated exocytosis of dense-core vesicles in neuro-
endocrine cells and in the secretion of a subset of
neurotransmitters (45, 46). The protein is a phospha-
tidylinositol 4,5-bisphosphate (PIP2)-binding protein
that acts after vesicle docking and priming (47),y e t
before calcium-triggered fusion and facilitates large
dense-core vesicle exocytosis (48).N o r t h e r nb l o t
analysis has conﬁrmed mRNA expression of CADPS in
the pituitary (47). The CADPS isolated from the
pituitary library did not possess the 50 end of the gene
sequence, essential for the correct folding of the protein.
Immunoreactivity to rCADPS was detected at a similar
frequency in both lymphocytic hypophysitis patients
and healthy controls.
We have also conﬁrmed that a minority of patients
with lymphocytic hypophysitis have autoantibodies
against PGSF2. Immunoreactivity against this protein
was previously reported in a small number of patients
with lymphocytic hypophysitis, isolated ACTH deﬁci-
ency, idiopathic TSH deﬁciency and other autoimmune
diseases. Tanaka et al. (17) also reported immuno-
reactivity against the pituitary-speciﬁc protein PGSF1a
in a similar cohort of patients. Immunoreactivity
against this protein has since been detected at a
high frequency in patients with rheumatoid arthritis,
suggesting it is more likely to be an autoantigen in
rheumatoidarthritisthanlymphocytichypophysitis(49).
a-Enolase antibodies in lymphocytic hypophysitis
have been well studied by immunoblotting (19) and
ITT and immunoprecipitation techniques (18). Auto-
antibodies are believed to be more of a prognostic
marker of autoimmunity itself rather than a speciﬁc
diagnostic marker. Lymphocytic hypophysitis patient
serum has also been shown to recognise the g isoform
of the enolase protein, NSE, on immunoblotting (20).
In this study, autoantibodies were only detected in
four patients, with patient sera previously positive
on immunoblotting, not positive in the ITT system.
This highlights the hazards of comparing results across
different assays.
ITT and immunoprecipitation have been employed
to analyse many autoantigens across multiple auto-
immune diseases. It has the advantage over other
techniques of high-afﬁnity autoantibodies recognising
three-dimensional conformational epitopes of the
expressed autoantigen, rather than the linear epitopes
of denatured proteins as with immunoblotting.
The method also provides a quantitative analysis of
high-throughput samples, with only small amounts of
both protein and serum sample required. However,
immunoprecipitation is not achievable with all proteins.
Adequate protein levels may not be produced in
some instances, as in the case of PGSF1a, and
additionally autoantibodies may not recognise the
autoantigen when not in its native in vivo form. Indeed
with CHD8 and piccolo, addition of DTT was required
for effective immunoprecipitation with the patient sera.
Finally, the results of ITT with NSE as an autoantigen
were totally different from those with the immuno-
blotting technique. Alternative techniques and
approaches may therefore be required to validate results
in certain cases.
There are several ongoing challenges in this ﬁeld. The
anterior pituitary has ﬁve hormone-secreting cell types,
each of which could have their own speciﬁc target
autoantigen(s) and whose autoimmune destruction
may present a different clinical picture. Our data show
that even immunoreactivity to a cell-speciﬁc transcrip-
tion factor, TPIT, is neither conﬁned to isolated ACTH
deﬁciency, nor does it seem completely hypophysitis
speciﬁc. Secondly, we have identiﬁed several proteins
involved in vesicle trafﬁcking as potential autoantigens.
Finally, as no control serum recognised more than one
protein, we suggest that a panel of target autoantigens
be developed and reactivity patterns be compared across
different clinical scenarios of autoimmune hypophysitis.
Even then, it may not be possible to differentiate the
different types of hypophysitis on the basis of autoanti-
bodies alone.
We have identiﬁed TPIT as a minor autoantigen in
lymphocytic hypophysitis, using a candidate approach.
We have also shown that immunoscreening of a
pituitary cDNA expression library is an effective way of
identifying candidate autoantigens in lymphocytic
hypophysitis, with ITT and subsequent immunoprecipi-
tation assays being a valuable method for their
evaluation. While the major autoantigen(s) were not
identiﬁed, re-screening with additional patient sera
holds the potential for isolating major autoantigens
and the development of an essential serological test for
lymphocytic hypophysitis.
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